caa a22 4500 606242724 CHVBK 20210128101320.0 cr unu---uuuuu 210128e20150301xx s 000 0 eng 10.1007/s12551-014-0153-3 doi (NATIONALLICENCE)springer-10.1007/s12551-014-0153-3 Surgery for hypertrophic cardiomyopathy [Elektronische Daten] [James Wu, Michael Seco, Caroline Medi, Chris Semsarian, David Richmond, Joseph Dearani, Hartzell Schaff, Michael Byrom, Paul Bannon] Hypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease characterised by otherwise unexplained myocardial hypertrophy of the left ventricle, and may result in left ventricular outflow tract obstruction. It is the most common cause of sudden cardiac death in young adults due to arrhythmias. Septal myectomy is a surgical treatment for HCM with moderate to severe outflow tract obstruction, and is indicated for patients with severe symptoms refractory to medical therapy. The surgical approach involves obtaining access to the interventricular septum via transaortic, transapical or transmitral approaches, and excising a portion of the hypertrophied myocardium to relieve the outflow tract obstruction. Large, contemporary series from centres experienced in septal myectomy patients have demonstrated a low early mortality of <2%, excellent long-term survival that matches the general population, and durable relief of symptoms. International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag Berlin Heidelberg, 2015 Hypertrophic cardiomyopathy nationallicence Septal myectomy nationallicence Alcohol septal ablation nationallicence Left ventricular outflow tract obstruction nationallicence Wu James Sydney Medical School, The University of Sydney, Sydney, Australia aut Seco Michael Sydney Medical School, The University of Sydney, Sydney, Australia aut Medi Caroline Molecular Cardiology Group, Centenary Institute, Sydney, NSW, Australia aut Semsarian Chris Sydney Medical School, The University of Sydney, Sydney, Australia aut Richmond David Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia aut Dearani Joseph Cardiac Surgery Unit, Mayo Clinic, Rochester, MN, USA aut Schaff Hartzell Cardiac Surgery Unit, Mayo Clinic, Rochester, MN, USA aut Byrom Michael The Baird Institute of Applied Heart & Lung Surgical Research, Sydney, Australia aut Bannon Paul Sydney Medical School, The University of Sydney, Sydney, Australia aut Biophysical Reviews Springer Berlin Heidelberg 7/1(2015-03-01), 117-125 1867-2450 7:1<117 2015 7 12551 https://doi.org/10.1007/s12551-014-0153-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s12551-014-0153-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wu James Sydney Medical School, The University of Sydney, Sydney, Australia aut NATIONALLICENCE 700 1- Seco Michael Sydney Medical School, The University of Sydney, Sydney, Australia aut NATIONALLICENCE 700 1- Medi Caroline Molecular Cardiology Group, Centenary Institute, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Semsarian Chris Sydney Medical School, The University of Sydney, Sydney, Australia aut NATIONALLICENCE 700 1- Richmond David Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Dearani Joseph Cardiac Surgery Unit, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Schaff Hartzell Cardiac Surgery Unit, Mayo Clinic, Rochester, MN, USA aut NATIONALLICENCE 700 1- Byrom Michael The Baird Institute of Applied Heart & Lung Surgical Research, Sydney, Australia aut NATIONALLICENCE 700 1- Bannon Paul Sydney Medical School, The University of Sydney, Sydney, Australia aut NATIONALLICENCE 773 0- Biophysical Reviews Springer Berlin Heidelberg 7/1(2015-03-01), 117-125 1867-2450 7:1<117 2015 7 12551